7,000 patients reached via MoST - March 2023
We have now screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study, with 620 people matching to companion trials and substudies.
We are also working to complete 12 of the 20 MoST substudies – of the other eight, four are now closed and four are in follow up.
We’re so grateful for all our partners helping deliver molecular screening and trials matching to Australians living with cancer.
We’re witnessing in real-time the power of research to transform lives and change the standard of cancer care.
Learn more about MoST here.